Batoclimab 340 mg SC weekly

DRUG2 trials

Sponsors

Immunovant Sciences GmbH

Conditions

Chronic Inflammatory Demyelinating PolyneuropathyGeneralized Myasthenia Gravis

Phase 2

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

TerminatedNCT05581199

Immunovant Sciences GmbHChronic Inflammatory Demyelinating Polyneuropathy

Start: 2022-12-15End: 2026-07-20Updated: 2026-08-11

Phase 3

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

TerminatedNCT05403541

Immunovant Sciences GmbHGeneralized Myasthenia Gravis

Start: 2022-06-27End: 2026-08-07Updated: 2026-09-14

Related Papers

Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.

Journal of Clinical Oncology2024-01-29

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial

BMJ Neurology Open2024-01-0116 citations